Pfizer has acquired the consumer healthcare business of Danish firm Ferrosan for an undisclosed fee in what the pharma giant says, “is an excellent strategic fit that strengthens our presence in dietary supplements”.
Sigma buys pharma standards firm RTC
Sigma-Aldrich has acquired analytical standards and certified reference materials manufacturer Resource Technology Corporation (RTC) to expand its analytical
Genzyme to sell intermediates biz to ICIG
Genzyme will sell its pharmaceutical intermediates business to International Chemical Investors Group (ICIG).
Valeant buys PharmaSwiss for CEE generics market
Canada’s Valeant Pharmaceuticals will pay €350m for PharmaSwiss to expand its presences in the central and eastern European generic drug market.
Abbott to cut 1,900 commercial & manufacturing jobs in US
Abbott Laboratories is to cut 1,900 US commercial and manufacturing jobs in response to healthcare reform and tough regulators.
Pharmsynthez buys Kevelt to grow in Europe
Russian drugmaker Pharmsynthez has bought Estonian manufacturer Kevelt in a bid to expand its international business.
Euticals to buy Archimica to expand manufacturing base
Italy-based API maker Euticals will buy fine chemicals firm Archimica from investment group TowerBrook Capital Partners.
New deals in the German drug packaging sector
Expansion has been a theme for German pharmaceutical packaging firms of late with the acquisition of Seidenader Maschinenbau by the Kober Group following just weeks after Edelmann bought a stake in Hungary’s Zalai Nyomda
Genzyme lowers guidance after Fabrazyme production delay
Genzyme has lowered 2011 financial projections after delaying the date it expects Fabrazyme production to return to normal.
Sun set on buying NextPharma and expanding it through acquisitions
NextPharma Technologies will be bought by Sun European Partners, the European adviser to US investment group Sun Capital Partners, in a deal announced late yesterday.
Aurobindo to sell Chinese ingredient unit to Sinopharm
Aurobindo Pharma is to sell its Chinese unit to Sinopharm as part of a strategic shift from low-margin ingredients to more profitable formulations.
Latest M&As in the pharmaceutical space
in-Pharmatechnologist presents a roundup of the latest deals and acquisitions in the pharmaceutical sector with news from Optima, SPI and DPS Engineering.
Top 5 biopharm cutback and closure articles of 2010
Big pharma continued to cut in 2010, closing plants and laying off staff in an attempt to cut costs and adjust post-merger. in-PharmaTechnologist presents a round up of five of the most read in 2010.
Aesica buys UCB plants and signs long-term supply deal
Aesica has bought three manufacturing sites from UCB, making its first foray into continental Europe and more than doubling its production capacity.
SurModics mulls pharma biz sale
SurModics said it may sell its pharmaceutical unit to focus on its medical device platform, I-vation delivery system and diagnostics businesses.
Reckitt Benckiser buys Paras
Reckitt Benckiser said it will pay INR32.6bn for Indian drugmaker Paras Pharmaceuticals to build its position in the consumer healthcare sector.
Cardinal Health acquires Chinese distributer as part of new ‘growth platform’
US based healthcare distributer, Cardinal Health, has announced the $470m acquisition of privately held healthcare distribution business Zuellig Pharma China, known locally as Yong Yu.
GSK to sell penicillin factory to Dr Reddy’s
GlaxoSmithKline will sell its oral penicillin manufacturing facility in Tennessee, US, to Dr Reddy’s for an undisclosed sum, along with US rights to its Augmentin and Amoxin brands.
Camlin Fine Chemicals’ board of directors OK Italian acquisition
Camlin Fine Chemicals has been given the green light from its board of directors to acquire an unnamed Italian fine chemicals manufacturer and form a subsidiary company to help boost its presence in the Middle East.
Genzyme looks at bids based on Campath performance in MS
Rumours suggest that Genzyme would consider accepting lower value takeover bids that take into account future performance of its cancer drug Campath in MS indications.
Roche to slash 4,800 jobs worldwide
Roche will cut 4,800 jobs worldwide over the next two years as part of a restructuring program designed to slash $2.4bn Swiss francs ($2.4bn) from annual costs.
AMRI posts loss, but forecasts 23% contract rev growth in Q4
API maker AMRI cited arbitration costs, efforts to address a US FDA warning letter and acquisitions as key factors in Q3 loss, but predicted that large-scale contract manufacturing business will drive final quarter gains.
Endo's takeover of Penwest gets shareholder approval
Penwest Pharmaceuticals shareholders have voted in favour of Endo Pharmaceuticals takeover plan, paving the way for the $144m merger.
ATMI acquires Artelis in ‘disposables’ deal
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
Hikma builds in US injectables sector with Baxter unit buy
Baxter International will sell its US generic injectables business to UK-based manufacturer Hikma Pharmaceuticals
US OKs Sanofi’s Genzyme bid; French strike hits Romainville plant
Sanofi Aventis has been given the go ahead to pursue US biotech Genzyme by the country’s antitrust authorities.
WR Grace’s acquisition of Synthetech approved by US Bankruptcy Court
Industrial catalysis firm WR Grace has been OKed to acquire fine chemicals group Synthetech by the US Bankruptcy Court.
Sanofi launches hostile Genzyme bid; Pfizer close on Uplyso Brazil deal
French drugmaker Sanofi Aventis has tabled an $18.5m, $69 per share, hostile takeover bid for Genzyme after failing to secure an amicable acquisition.
Lupin hold majority stake in Generic Health
Lupin has notified the Bombay Stock Exchange (BSE) that is has acquired a majority stake in Australian pharmaceutical company, Generic Health.
DSM seeks Asian partners; welcomes J&J Crucell takeover
DSM aims to keep pace with the rapid evolution of pharmaceutical sector through increased partnering and a focus on Asia.
Solvay integration will cost manufacturing jobs, says Abbott
Abbott Laboratories says it will shed manufacturing jobs as part integration of the pharmaceutical business it bought from Solvay earlier this year.
Actavis looks to enter biosimilars through acquisition
Actavis is looking to enter the biosimilars sector through the proposed acquisition of a stake in Biopartners.
Genzyme rejects Sanofi’s $18.5bn bid; IPT looks at biotech’s turbulent 18-months
Genzyme has rejected Sanofi-Aventis' $18.5bn (€14.5bn) takeover bid, describing it as offering no improvement in price on the previous proposal and failing “to establish a basis for engagement.”
Lonza buys Vivante to expand custom biologics biz
Lonza buys viral-based biologics maker Vivante GMP Solutions to broaden custom manufacturing offering.
Amcor: Alcan costs cut profits; but pharma flexibles unit boosts sales
The Flexibles packaging unit acquired in Alcan Packaging deal boost sales, but integration costs hit fiscal 2010 net profit at Australia’s Amcor.
Cipla to buy Meditab for $28m
Indian pharmaceutical firm Cipla is to buy Meditab Specialties to boost active pharmaceutical ingredient (API) and intermediate production capacity.
India ponders compulsory licensing revisions to cut prices
India is considering strengthening compulsory licensing provisions, which allow third parties to produce patented products, in response to concerns about overseas takeovers and drug prices.
Imclone closes US Erbitux plant
Imclone has closed the manufacturing facility in Branchburg, New Jersey where it produces the cancer drug Erbitux, according to reports in the US media.
Merck to buy back Riverside plant for key API supply
US drugmaker Merck & Co has announced plans to reacquire a Pennsylvania manufacturing plant to guarantee supply of key active pharmaceutical ingredient (API).
Endo to buy Penwest for Opana ER tech
Endo Pharmaceuticals will pay $168m (€127.7m) for drug delivery tech and formulations firm Penwest Pharmaceuticals in bid to expand pain portfolio.
US patients call for Fabrazyme patent break; Are you watching Sanofi?
Calls for US government to break Genzyme’s Fabrazyme patents accompany more speculation that French drugmaker Sanofi Aventis is in takeover talks.
Bilcare to boost EU and US access with €100m Ineos Films buy
Bilcare to buy Ineos’ rigid polymer films business for €100m ($132m) to improve access to pharmaceutical packaging customers worldwide.
Heinkel boosts separation offering with Comber buy
Heinkel expands pharmaceutical filtering and drying systems business with acquisition of Italian equipment maker Comber.
Pharma consolidation and the downstream impact on CROs
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Colorcon builds coating biz with Indian buy
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.
Constantia buys Tobepal from Amcor
Austria’s Constantia Packaging will pay Amcor €92m ($118m) for its Spanish Tobepal flexible packaging business.
Merck Millipore launched after $7bn takover
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys...
Merck to close eight production facilities, eight R&D labs
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
Sanofi said to be planning $20bn acquisition in US
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.